Semaglutide for weight loss and cardiometabolic risk reducti... : Current Opinion in Cardiology
Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity : Current …

Semaglutide is a glucagon-like peptide-1 receptor agonist that was recently approved by the
US Food and Drug Administration for chronic weight management. This paper reviews data …

Abstract Background/Objective There are limited real-world studies assessing semaglutide
weight loss and associated comorbidity and metabolic outcomes over periods≥ 6 months …

People with overweight or obesity often suffer from associated cardiometabolic diseases
and comorbidities. Current therapies for obesity include lifestyle intervention, bariatric …

Obesity is a major public health issue with an increasing prevalence worldwide. Excess
body fat is associated with various comorbidities, as well as increased overall mortality risk …

Background: Conventional lifestyle and pharmacologic interventions alone result in only
modest long-term weight loss in patients with moderate-to-severe obesity. We evaluated …

Background: The 2-year efficacy and safety of once-weekly (OW) subcutaneous semaglutide
2.4 mg vs placebo in adults with overweight/obesity was assessed in the STEP 5 phase 3 …

Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated clinically
important weight loss effects in patients with type 2 diabetes. However, its effects on …

More than half the world population is expected to be overweight or obese by the year 2035
[1]. Obesity and atherosclerotic cardiovascular disease have always been a fatal …

Cardiovascular disease (CVD) is a leading global cause of death, with preventable risk
factors like obesity contributing most to it. Obesity's association with CVD originate from …